Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3775876
Max Phase: Preclinical
Molecular Formula: C15H23N3Na4O6P2
Molecular Weight: 407.34
Molecule Type: Small molecule
Associated Items:
ID: ALA3775876
Max Phase: Preclinical
Molecular Formula: C15H23N3Na4O6P2
Molecular Weight: 407.34
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)=CCC/C(C)=C/CCn1cc(CC(P(=O)([O-])[O-])P(=O)([O-])[O-])nn1.[Na+].[Na+].[Na+].[Na+]
Standard InChI: InChI=1S/C15H27N3O6P2.4Na/c1-12(2)6-4-7-13(3)8-5-9-18-11-14(16-17-18)10-15(25(19,20)21)26(22,23)24;;;;/h6,8,11,15H,4-5,7,9-10H2,1-3H3,(H2,19,20,21)(H2,22,23,24);;;;/q;4*+1/p-4/b13-8+;;;;
Standard InChI Key: DTOZLXJMIAVMAQ-MEVDHSCASA-J
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 407.34 | Molecular Weight (Monoisotopic): 407.1375 | AlogP: 2.58 | #Rotatable Bonds: 10 |
Polar Surface Area: 145.77 | Molecular Species: ACID | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 1.25 | CX Basic pKa: 0.26 | CX LogP: 0.63 | CX LogD: -3.81 |
Aromatic Rings: 1 | Heavy Atoms: 26 | QED Weighted: 0.34 | Np Likeness Score: 0.36 |
1. Wills VS, Allen C, Holstein SA, Wiemer DF.. (2015) Potent Triazole Bisphosphonate Inhibitor of Geranylgeranyl Diphosphate Synthase., 6 (12): [PMID:26713103] [10.1021/acsmedchemlett.5b00334] |
2. Wills VS, Metzger JI, Allen C, Varney ML, Wiemer DF, Holstein SA.. (2017) Bishomoisoprenoid triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase., 25 (8): [PMID:28302510] [10.1016/j.bmc.2017.02.066] |
3. Matthiesen RA, Varney ML, Xu PC, Rier AS, Wiemer DF, Holstein SA.. (2018) α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors., 26 (2): [PMID:29248353] [10.1016/j.bmc.2017.10.023] |
4. Matthiesen RA, Varney ML, Xu PC, Rier AS, Wiemer DF, Holstein SA.. (2018) α-Methylation enhances the potency of isoprenoid triazole bisphosphonates as geranylgeranyl diphosphate synthase inhibitors., 26 (2): [PMID:29248353] [10.1016/j.bmc.2017.10.023] |
Source(1):